StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acceleron Pharma (XLRN) PT Raised to $62 at UBS
July 10, 2018 8:01 AM
UBS raised its price ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Next Articles
Acceleron Pharma (XLRN) Granted FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy
July 12, 2018 7:10 AM
Acceleron Pharma (XLRN) PT Raised to $74 at H.C. Wainwright Following Positive BELIEVE Results
July 10, 2018 7:34 AM
Piper Jaffray Downgrades Acceleron Pharma (XLRN) to Neutral
July 10, 2018 6:31 AM
Acceleron (XLRN) option implied volatility flat into Phase III Believe results
July 10, 2018 5:24 AM
After-Hours Stock Movers 07/09: (OCX) (XLRN) (HEAR) Higher; (AQXP) (SPRO) (WHD) Lower (more...)
July 9, 2018 5:54 PM
Form 8-K ACCELERON PHARMA INC For: Jul 09
July 9, 2018 5:02 PM
Celgene (CELG), Acceleron (XLRN) Report Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III BELIEVE Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 9, 2018 4:53 PM
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia
July 9, 2018 4:52 PM
